<DOC>
	<DOCNO>NCT00004083</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal cisplatin treat patient recurrent ovarian cancer .</brief_summary>
	<brief_title>Liposomal Cisplatin Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient recurrent platinum sensitive ovarian epithelial cancer treat cisplatin liposomal ( SPI-77 ) . II . Determine time response , duration response , time progression , survival patient treat regimen . III . Characterize safety regimen patient . OUTLINE : Patients receive cisplatin liposomal ( SPI-77 ) IV minimum 4 hour day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients clinical benefit 6 course may receive additional course upon approval pharmaceutical sponsor . Patients follow every 2 month minimum 6 month periodically survival . PROJECTED ACCRUAL : A total 26-63 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven recurrent ovarian epithelial cancer Metastatic disease allow Must receive prior platinum contain chemotherapy Must consider platinum sensitive following : Response prior platinum contain regimen No disease progression prior platinum contain regimen Disease free interval great 6 month follow platinum contain regimen At least 1 bidimensionally measurable lesion No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST great 2 time upper limit normal Albumin least 2.5 g/dL Renal : Creatinine clearance least 50 mL/min Cardiovascular : No uncontrolled heart disease abnormal symptomatic cardiac function Other : Must baseline hearing evaluation include audiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No acute infection require systemic therapy No sign confusion disorientation prior major psychiatric illness may preclude informed consent No grade 3 4 neurotoxicity prior anticancer treatment grade 2 high neuropathy cause No requirement total parental nutrition lipids No prior allergic reaction cisplatin platinum containing product PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior SPI77 At least 3 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , suramin ) No concurrent antineoplastic agent Endocrine therapy : No concurrent hormonal anticancer therapy Radiotherapy : At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 2 week since prior major surgery cancer Other : At least 30 day since prior investigational agent No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>